Monday, June 2, 2025

Latest

Revive Therapeutics Continues With Phase 3 Clinical Trial For Bucillamine, To File For Emergency Use Authorization

Revive Therapeutics (CSE: RVV) issued an update to the market this morning related to its phase 3 clinical trial for the use of bucillamine for the treatment of COVID-19. The company has indicated that it is on pace to meet enrollment goals for the independent data and safety monitoring board’s data and safety review.

The board is slated to review the safety and efficacy data on 210 patients required within the first interim analysis of patients whom are then followed up for 28 days after the randomization process. Active monitoring of the first interim analysis by the company has found no safety concerns and no severe adverse events throughout the enrollment period.

Nine clinical sites are currently participating in the phase 3 study, with a further six sites to begin participating in January. The company currently has an enrollment goal of up to 1,000 patients. The company also revealed this morning that it intends to file for an Emergency Use Authorization for the use of bucillamine as a treatment for mild to moderate COVID-19 with the US Food and Drug Administration.

Revive Therapeutics last traded at $0.63 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

First Majestic Silver: The Santo Nino Discovery

Avino Silver Q1 Earnings: The Record Streak Continues!

Aya Gold & Silver Q1 Earnings: From Kitchen Sink to Record Results

Recommended

Emerita Resources Intends To Appeal Exploitation License Granted To Minera Los Frailes

First Majestic Silver: The Santo Nino Discovery

Related News

Revive Therapeutics To Expand Clinical Sites For Covid-19 Related Phase 3 Study

Revive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase...

Friday, February 26, 2021, 08:54:19 AM

Revive Therapeutics, Pharmather Partner On Psilocybin Cancer Research

Revive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research...

Wednesday, November 18, 2020, 07:30:40 AM

Revive Therapeutics Doubles Bought Deal Financing To $20.0 Million

Revive Therapeutics (CSE: RVV) has upsized the bought deal financing announced last night. Originally pegged...

Thursday, January 21, 2021, 10:04:38 AM

Revive Therapeutics Conducts $10.0 Million Bought Deal Financing

Revive Therapeutics (CSE: RVV) this evening announced that it will be conducting a bought deal...

Wednesday, January 20, 2021, 08:37:25 PM

Revive Therapeutics Granted FDA Approval For Phase 3 Clinical Trial For Bucillamine In COVID-19 Treatment

It’s a big day for Revive Therapeutics (CSE: RVV) (OTC: RVVTF). The company announced this...

Friday, July 31, 2020, 09:16:29 AM